Docoh
Loading...

PTGX Protagonist Therapeutics

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a 150 patient Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional second-generation oral interleukin-23 receptor antagonist candidates PN-235 and PN-232, are in early stages of clinical development. The Company has developed a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Company profile

Ticker
PTGX
Exchange
CEO
Dinesh V. Patel
Employees
Incorporated
Location
Fiscal year end
Former names
Protagonist Inc, Protagonist Therapeutics Inc
SEC CIK
Subsidiaries
Protagonist Pty Limited ...
IRS number
980505495

PTGX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 21
19 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 192.64M 192.64M 192.64M 192.64M 192.64M 192.64M
Cash burn (monthly) (positive/no burn) (positive/no burn) 10.29M 6.8M 7.9M 7.3M
Cash used (since last report) n/a n/a 37.7M 24.89M 28.93M 26.74M
Cash remaining n/a n/a 154.93M 167.74M 163.7M 165.9M
Runway (months of cash) n/a n/a 15.1 24.7 20.7 22.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Sep 21 Dinesh V PH D Patel Common Stock Option exercise Acquire M No No 4.21 40,000 168.4K 492,158
21 Sep 21 Dinesh V PH D Patel Stock Option Common Stock Option exercise Dispose M No No 4.21 40,000 168.4K 125,742
17 Aug 21 David Y Liu Common Stock Sell Dispose S No Yes 47.56 14,779 702.89K 58,254
17 Aug 21 David Y Liu Common Stock Option exercise Acquire M No No 0.87 10,000 8.7K 73,033
17 Aug 21 David Y Liu Stock Option Common Stock Option exercise Dispose M No No 0.87 10,000 8.7K 13,767
27 May 21 Giraudo Bryan Stock Option Common Stock Grant Acquire A No No 35.23 18,000 634.14K 18,000
27 May 21 Noonberg Sarah B. Stock Option Common Stock Grant Acquire A No No 35.23 18,000 634.14K 18,000
27 May 21 O'Dowd Sarah A Stock Option Common Stock Grant Acquire A No No 35.23 18,000 634.14K 18,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 137 129 +6.2%
Opened positions 26 25 +4.0%
Closed positions 18 26 -30.8%
Increased positions 59 43 +37.2%
Reduced positions 35 41 -14.6%
13F shares
Current Prev Q Change
Total value 2.91B 1.84B +58.3%
Total shares 54.66M 51.09M +7.0%
Total puts 51.5K 43.3K +18.9%
Total calls 23.1K 27.2K -15.1%
Total put/call ratio 2.2 1.6 +40.0%
Largest owners
Shares Value Change
FMR 7.12M $319.38M +8.3%
Biotechnology Value Fund L P 4.27M $86.18M 0.0%
BVF 3.75M $168.48M -5.2%
RTW Investments 3.51M $157.41M 0.0%
Consonance Capital Management 3.45M $154.7M +27.2%
BLK Blackrock 3.04M $136.46M +1.3%
JNJ Johnson & Johnson 2.45M $49.38M 0.0%
Johnson & Johnson Innovation - JJDC 2.45M $109.92M 0.0%
Farallon Capital Management 2.33M $104.56M -3.9%
Vanguard 2.29M $102.69M +6.9%
Largest transactions
Shares Bought/sold Change
Baker Bros. Advisors 455.28K -980.92K -68.3%
Victory Capital Management 845.2K +845.2K NEW
DB Deutsche Bank AG - Registered Shares 821.72K +796.16K +3114.7%
Consonance Capital Management 3.45M +737.17K +27.2%
FMR 7.12M +545.16K +8.3%
Loomis Sayles & Co L P 536.92K +536.92K NEW
Obermeyer Wood Investment Counsel, LLLP 761.02K +374.95K +97.1%
Commodore Capital 0 -349.6K EXIT
Novo Holdings A/S 600.01K -267.71K -30.9%
STT State Street 1.45M -258.06K -15.1%

Financial report summary

?
Management Discussion
  • License and collaboration revenue decreased $4.0 million, or 64%, from $6.2 million for the three months ended June 30, 2020 to $2.3 million for the three months ended June 30, 2021, which was primarily related to a decrease in services provided under the Janssen License and Collaboration Agreement recognized based on proportional performance. The level of services has decreased as the Company nears completion of its performance obligations delivered pursuant to the collaboration, including the anticipated completion of its ongoing PN-235 Phase 1 trial in the fourth quarter of 2021 and its ongoing PN-232 Phase 1 trial in the first half of 2022.
  • We have determined that the transaction price of the initial performance obligation under the Janssen License and Collaboration Agreement was $95.8 million as of June 30, 2021, a decrease of $0.5 million from the transaction price of $96.3 million as of March 31, 2021. In order to determine the transaction price, we evaluated all payments expected to be received during the duration of the contract, net of development costs reimbursement expected to be payable to Janssen. We determined that the transaction price includes the $50.0 million upfront payment, the $25.0 million payment received upon the effectiveness of the First Amendment, the $5.0 million payment triggered by the successful nomination of a second-generation compound, $17.9 million of reimbursement from Janssen for services performed for PTG-200 Phase 2 and for second-generation compound research costs and other services, and estimated
  • variable consideration consisting of a $7.5 million milestone payment subject to the completion of a Phase 1 study for a second-generation compound, offset by $9.6 million of net cost reimbursement to Janssen for services performed. The decrease in transaction price from March 31, 2021 to June 30, 2021 was due primarily to a decrease in the forecast of cost reimbursements to Janssen for services performed. We re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Breakthrough, capacity, EHA, feet, parallel, pathway, preceding, PTG, reopening, space, square, thrombotic, Upcoming
Removed: controlling, gastrointestinal, paradigm, timeline

Patents

GRANT
Utility
α4α7 peptide monomer and dimer antagonists
7 Sep 21
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
APP
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
26 Aug 21
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
GRANT
Utility
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
22 Jun 21
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
APP
Utility
Analogues of Hepcidin Mimetics with Improved In Vivo Half Lifes
20 May 21
The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
GRANT
Utility
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
9 Mar 21
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.